Bladder Cancer - Results from #220

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. January 8, 2025

Bowel regimens before radical cystectomy: An analysis of a modern cohort. January 8, 2025

The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary January 7, 2025

Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness. January 7, 2025

Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer. January 7, 2025

Comprehensive genomic characterization of early-stage bladder cancer. January 7, 2025

Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. January 7, 2025

Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study. January 6, 2025

Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy. January 6, 2025

TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes. January 3, 2025

Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials. January 3, 2025

Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study. January 2, 2025

Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer. January 2, 2025

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. January 1, 2025

Does time matter in early radical cystectomy? Comparing outcome, clinical and pathological characteristics of immediate versus deferred radical cystectomy. December 31, 2024

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. December 31, 2024

The Financial Burden of Localized and Metastatic Bladder Cancer. December 30, 2024

Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis. December 30, 2024

Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI. December 27, 2024

Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series. December 27, 2024

Page 12 of 535